- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00492544
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age
Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine 580299 When Administered as a 3-dose Schedule in Healthy Japanese Pre-adolescent and Adolescent Female Subjects.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
- GSK Investigational Site
-
-
-
-
-
Saitama, Japan, 360-0846
- GSK Investigational Site
-
Saitama, Japan, 360-0812
- GSK Investigational Site
-
Tokyo, Japan, 154-0024
- GSK Investigational Site
-
Tokyo, Japan, 136-0073
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects who the investigator/co-investigator believes that they and/or their parent(s)/legally acceptable representative(s) can and will comply with the requirements of the protocol should be enrolled in the study.
- A Japanese female between, and including, 10 and 15 years of age at the time of the first vaccination.
- Written informed consent obtained from the parent(s) or legally acceptable representative(s) of the subject. In addition, a written informed assent must be obtained from the subject prior to enrolment.
- Healthy subjects as established by medical history and history-directed clinical examination before entering into the study.
- All subjects must have a negative urine pregnancy test.
- Subjects must be of non-childbearing potential, or, if of childbearing potential, they must be abstinent or have used adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series. Non-abstinent pre-menarche subjects, as well as subjects who reach menarche during study, must follow the same precautions.
Exclusion Criteria:
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose or planned during study.
- Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after the first dose of vaccine. Administration of vaccines up to 8 days before the first dose of study vaccine is allowed. Enrolment will be deferred until the subject is outside of specified window.
- Concurrently participating in another clinical study, at any time during the study period (up to Month 7), in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- Previous vaccination against HPV, or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period (Day 0 to Month 7).
- Previous administration of components of the investigational vaccine .
- Cancer or autoimmune disease under treatment.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- Hypersensitivity to latex.
- Acute disease at the time of enrolment.
- Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory tests.
- Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
- Pregnant or breastfeeding subject.
- Subject planning to become pregnant or planning to discontinue contraceptive precautions.
- Oral temperature ≥ 37.5°C/Axillary temperature ≥ 37.5°C.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cervarix
Subjects received 3 doses of Cervarix™ (HPV-16/18 L1 VLP AS04) according to a 0, 1, 6-month schedule.
|
Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects Reporting Solicited General Symptoms
Time Frame: During the 7-day (Days 0-6) period following each vaccination
|
Solicited general symptoms assessed include arthralgia, fatigue, fever, gastrointestinal symptoms, headache, myalgia, rash, and urticaria.
|
During the 7-day (Days 0-6) period following each vaccination
|
Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies
Time Frame: One month post Dose 3 (Month 7)
|
Seroconversion is defined as the appearance of anti-HPV-16 and/or anti-HPV-18 antibodies (i.e. antibody titer ≥ cut-off value) in the sera of subjects seronegative before vaccination. Cut-off values were 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti-HPV-18 antibodies. |
One month post Dose 3 (Month 7)
|
Anti-HPV-16 and Anti-HPV-18 Antibody Titers
Time Frame: Before vaccination (PRE) and one month post Dose 3 (Month 7)
|
Titers are given as geometric mean titers (GMTs) calculated on all subjects.
|
Before vaccination (PRE) and one month post Dose 3 (Month 7)
|
Number of Subjects Reporting Solicited Local Symptoms
Time Frame: During the 7-day (Days 0-6) period following each vaccination
|
Solicited local symptoms assessed include pain, redness and swelling.
|
During the 7-day (Days 0-6) period following each vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects Reporting Unsolicited Adverse Events (AE)
Time Frame: During the 30-day (Days 0-29) period following each vaccination
|
Unsolicited adverse event= Any adverse event (AE) reported in addition to those solicited during the clinical study.
Also any "solicited" symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.
|
During the 30-day (Days 0-29) period following each vaccination
|
Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) and Other Medically Significant Conditions
Time Frame: From Day 0 up to Month 7
|
NOCDs assessed include e.g.
autoimmune disorders, asthma, type I diabetes.
Medically significant conditions assessed include adverse events prompting emergency room visits and physician office visits not related to common illnesses or Serious Adverse Events that are not related to common illnesses.
|
From Day 0 up to Month 7
|
Outcome of All Pregnancies
Time Frame: Up to Month 7
|
According to the study protocol, the outcome of all pregnancies reported during the entire study period was to be reported, even if delivery occurs after the end of the study.
|
Up to Month 7
|
Number of Subjects Reporting Serious Adverse Events (SAEs)
Time Frame: From Day 0 up to Month 7
|
Serious adverse events assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
|
From Day 0 up to Month 7
|
Number of Subjects Reporting Clinically Relevant Abnormalities in Biochemical and Haematological Parameters
Time Frame: At Day 0 and Month 7
|
Abnormalities include values outside (above or below) the normal ranges. Normal ranges: alanine aminotransferase (ALT): 5-35 U/L aspartate aminotransferase (AST): 5-50 U/L basophils: 0-2 % bilirubin total: 0.1-1.1 mg/dL blood urea nitrogen: 0-20 mg/dL creatinine: 0.2-1.2 mg/dL eosinophils: 0-7 % hematocrit: 30-45 % hemoglobin: 10-15 g/dL lymphocytes: 18-50 % monocytes: 1-8 % neutrophils: 42-74 % platelets: 10-60 10E4/microL red blood cells: 350-550 10E4/microL total protein: 6.5-8.6 g/dL white blood cells: 4000-15000 /microL |
At Day 0 and Month 7
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 110168
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study Data/Documents
-
Dataset Specification
Information identifier: 110168Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 110168Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 110168Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 110168Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: 110168Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 110168Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 110168Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections, Papillomavirus
-
The AlfredMerck Sharp & Dohme LLCCompletedHuman Papillomavirus Infection | Human PapillomavirusAustralia
-
CHU de Quebec-Universite LavalCentre hospitalier de l'Université de Montréal (CHUM); Institut National en... and other collaboratorsCompletedHuman Papillomavirus InfectionsCanada
-
Kanazawa Medical UniversityMerck Sharp & Dohme LLCUnknownPapillomavirus Infections | Papillomavirus Vaccines
-
University of North Carolina, Chapel HillCenters for Disease Control and Prevention; American Cancer Society, Inc.; New... and other collaboratorsWithdrawnHuman Papillomavirus InfectionUnited States
-
Merck Sharp & Dohme LLCCompletedHuman Papillomavirus Infection
-
Sanford HealthCompletedHuman Papillomavirus InfectionUnited States
-
GlaxoSmithKlineCompletedHuman Papillomavirus InfectionBahrain
-
Centre Hospitalier Universitaire de BesanconCompletedHuman Papillomavirus InfectionFrance
-
University Hospital, GenevaCompletedHuman Papillomavirus InfectionSwitzerland
-
University of ConnecticutCompletedHuman Papillomavirus Infection
Clinical Trials on Cervarix™ (HPV-16/18 L1 VLP AS04)
-
GlaxoSmithKlineCompletedInfections, PapillomavirusChina
-
GlaxoSmithKlineCompletedInfections, PapillomavirusMalaysia
-
GlaxoSmithKlineCompletedInfections, PapillomavirusHong Kong
-
GlaxoSmithKlineCompletedInfections, PapillomavirusBelgium, United States
-
National Institute for Control of Vaccine and BiologicalsUnknownHuman Papillomavirus (HPV) VaccineVietnam
-
GlaxoSmithKlineCompletedInfections, PapillomavirusKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, PapillomavirusIndia
-
National Cancer Institute (NCI)Active, not recruitingHuman Papillomavirus-Related Cervical CarcinomaCosta Rica
-
GlaxoSmithKlineCompletedInfections, PapillomavirusCanada, Denmark, Hungary, Sweden
-
GlaxoSmithKlineCompletedInfections, PapillomavirusCanada, United States, Brazil